RE:RE:RE:Will add if they continue to push it down.I think that we are dfininately in a better position now after the goblet results and think that the almost 30% pullback is temporary and most likely not justified although that is the nature of ONC.
Also for clarification on the solidly derisked trial I beflieve Douglas Loe is referring to the pancreatic trial and not the mbc trial as per the following quote.
"Oncolytics continues to test pelareorep in combination with other checkpoint inhibitor biologics, though with focus on metastatic breast cancer and advanced pancreatic cancer, the latter now solidly de-risked by GOBLET-1 data."
Better times ahead just hope it is sooner than the Douglas Loe thought that we will be partnered for phase 3 in 2024. Someone will most likely step up sooner and hard to say where it will all land as I am sure that pfizer is up to date on Bracelet results as they have access to real time. Still wish that ONC would have stuck to releasing some Top line data in December as previously stated as this would have helped the cause for the sp and created a more competative evironment assuming of course that the Bracelet results are what we are hoping that they are.